{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:14:58Z","timestamp":1788264898496,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The anthrax lethal toxin neutralization assay (TNA) will likely be used to correlate the protection offered by new anthrax vaccines in animal models to the immunogenicity that will be provided in humans. TNA data are being generated in several different laboratories to measure the immune responses in rabbits, nonhuman primates, and humans. In order to compare data among species and laboratories, a collaborative study was conducted in which 108 samples from the three species were analyzed in seven independent laboratories. Six of the seven laboratories had participated in an interlaboratory technology transfer of the TNA. Analysis of the titration curves generated by samples from each species indicated that the behaviors of the samples from all species were similar; the upper and lower asymptotes and the slopes of the curves were less than 30% divergent from those for human reference material. Dilutional linearity was consistent among samples from each species, with spike to effective dilution at 50% inhibition (ED\n            <jats:sub>50<\/jats:sub>\n            ) slopes of less than 1.2 for all species. Agreement among the laboratories with consensus values was within 10% of the ED\n            <jats:sub>50<\/jats:sub>\n            s for all samples and within 7.5% of the quotients of the test sample ED\n            <jats:sub>50<\/jats:sub>\n            and the reference standard ED\n            <jats:sub>50<\/jats:sub>\n            (NF\n            <jats:sub>50<\/jats:sub>\n            s) for all samples. The relative standard deviations obtained when data from all laboratories and for all species were combined were 45% for the ED\n            <jats:sub>50<\/jats:sub>\n            s and 35% for the NF\n            <jats:sub>50<\/jats:sub>\n            s. These precision data suggest that the NF\n            <jats:sub>50<\/jats:sub>\n            readout may normalize the values generated by different laboratories. This study demonstrates that the TNA is a panspecies assay that can be performed in several different laboratories with a high degree of quantitative agreement and precision.\n          <\/jats:p>","DOI":"10.1128\/cvi.00003-08","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T01:38:37Z","timestamp":1208396317000},"page":"946-953","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Interlaboratory Comparison of Results of an Anthrax Lethal Toxin Neutralization Assay for Assessment of Functional Antibodies in Multiple Species"],"prefix":"10.1128","volume":"15","author":[{"given":"Kristian S.","family":"Omland","sequence":"first","affiliation":[{"name":"Precision Bioassay, Burlington, Vermont"},{"name":"Battelle Eastern Science and Technology Center, Aberdeen, Maryland"},{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Brys","sequence":"additional","affiliation":[{"name":"Precision Bioassay, Burlington, Vermont"},{"name":"Battelle Eastern Science and Technology Center, Aberdeen, Maryland"},{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lansky","sequence":"additional","affiliation":[{"name":"Precision Bioassay, Burlington, Vermont"},{"name":"Battelle Eastern Science and Technology Center, Aberdeen, Maryland"},{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Clement","sequence":"additional","affiliation":[{"name":"Precision Bioassay, Burlington, Vermont"},{"name":"Battelle Eastern Science and Technology Center, Aberdeen, Maryland"},{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freyja","family":"Lynn","sequence":"additional","affiliation":[{"name":"Precision Bioassay, Burlington, Vermont"},{"name":"Battelle Eastern Science and Technology Center, Aberdeen, Maryland"},{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Model selection and multimodel inference: a practical information-theoretical approach 2nd. 2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","volume":"3","year":"2007","unstructured":"Campbell, J. D., K. H. Clement, S. S. Wasserman, S. Donegan, L. Chrisley, and K. L. Kotloff. 2007. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccines3:205-211.","journal-title":"Hum. Vaccines"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.1.245-252.1993"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","volume":"24","year":"2006","unstructured":"Gorse, G. J., W. Keitel, H. Keyserling, D. N. Taylor, M. Lock, K. Alves, J. Kenner, L. Deans, and M. Gurwith. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine24:5950-5959.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","first-page":"127","volume":"59","year":"2005","unstructured":"Hauck, W. W., R. C. Capen, J. D. Callahan, J. E. De Muth, H. Hsu, D. Lansky, N. C. Sajjadi, S. S. Seaver, R. R. Singer, and D. Weisman. 2005. Assessing parallelism prior to determining relative potency. PDA J. Pharm. Sci. Technol.59:127-137.","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","volume":"32","year":"2004","unstructured":"Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace-Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals32:17-27.","journal-title":"Biologicals"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","volume":"16","year":"1998","unstructured":"Ivins, B. E., M. L. M. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine16:1141-1148.","journal-title":"Vaccine"},{"key":"e_1_3_2_9_2","first-page":"61","volume":"271","year":"2002","unstructured":"Lacy, D. B., and R. J. Collier. 2002. Structure and function of anthrax toxin. Curr. Top. Microbiol. Immunol.271:61-85.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.01.007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","volume":"22","year":"2004","unstructured":"Little, S. F., B. E. Ivins, P. F. Fellows, M. L. M. Pitt, S. L. W. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine22:422-430.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_3_2_13_2","unstructured":"NIAID biodefense research agenda for CDC category A agents. 2002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.794-797.2006"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.4.617-629.2004"},{"key":"e_1_3_2_16_2","unstructured":"nlme: linear and nonlinear mixed effects models. 2007"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","volume":"19","year":"2001","unstructured":"Pitt, M. L. M., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine19:4768-4773.","journal-title":"Vaccine"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","volume":"20","year":"2002","unstructured":"Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine20:1412-1420.","journal-title":"Vaccine"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.vaccine.2006.01.054","volume":"24","year":"2006","unstructured":"Pittman, P. R., S. L. Norris, J. G. Oro, D. Bedwell, T. L. Cannon, and K. T. Mckee. 2006. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine24:3654-3660.","journal-title":"Vaccine"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.11.4.330-334.1963"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1086\/423937","volume":"190","year":"2004","unstructured":"Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, A. E. Freeman, C. M. Elie, S. K. Martin, C. Greene, R. D. Aubert, J. Glidewell, B. A. Perkins, R. Ahmed, and D. S. Stephens. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis.190:1228-1236.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","volume":"8","year":"2002","unstructured":"Quinn, C. P., V. A. Semenova, C. M. Elie, S. Romero-Steiner, C. Greene, H. Li, K. Stamey, E. Steward-Clark, D. S. Schmidt, E. Mothershed, J. Pruckler, S. Schwartz, R. F. Benson, L. O. Helsel, P. F. Holder, S. E. Johnson, M. Kellum, T. Messmer, W. L. Thacker, L. Besser, B. D. Plikaytis, T. H. Taylor, A. E. Freeman, K. J. Wallace, P. Dull, J. Sejvar, E. Bruce, R. Moreno, A. Schuchat, J. R. Lingappa, N. Marano, S. K. Martin, J. Walls, M. Bronsdon, G. M. Carlone, M. Bajani-Ari, D. A. Ashford, D. S. Stephens, and B. A. Perkins. 2002. Specific, sensitive, and quantitative enzyme-linked Immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis.8:1103-1110.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_23_2","unstructured":"R: a language and environment for statistical computing. 2007"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2888-2893.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biologicals.2006.07.003","volume":"35","year":"2007","unstructured":"Selinsky, C. L., V. D. Whitlow, L. R. Smith, D. C. Kaslow, and H. M. Horton. 2007. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human IgG antibodies to anthrax lethal factor antigen. Biologicals35:123-129.","journal-title":"Biologicals"},{"key":"e_1_3_2_26_2","first-page":"919","volume":"11","year":"2004","unstructured":"Semenova, V. A., E. Steward-Clark, K. L. Stamey, T. H. Taylor, D. S. Schmidt, S. K. Martin, N. Marano, and C. P. Quinn. 2004. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin. Diagn. Lab. Immunol.11:919-923.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_27_2","first-page":"653","volume":"31","year":"2005","unstructured":"Tan, C. Y. 2005. RSD and other variability measure of the lognormal distribution. Pharmacopeial Forum31:653-655.","journal-title":"Pharmacopeial Forum"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.394-398.2006"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00003-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00003-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:40:23Z","timestamp":1627591223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00003-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1128\/CVI.00003-08"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00003-08","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"2008-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}